Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration.
Porcu P, Eisenbeis CF, Pelletier RP, Davies EA, Baiocchi RA, Roychowdhury S, Vourganti S, Nuovo GJ, Marsh WL, Ferketich AK, Henry ML, Ferguson RM, Caligiuri MA. Porcu P, et al. Among authors: ferketich ak. Blood. 2002 Oct 1;100(7):2341-8. doi: 10.1182/blood-2002-01-0210. Blood. 2002. PMID: 12239141 Free article.
Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S, Baiocchi RA, Vourganti S, Bhatt D, Blaser BW, Freud AG, Chou J, Chen CS, Xiao JJ, Parthun M, Chan KK, Eisenbeis CF, Ferketich AK, Grever MR, Chen CS, Caligiuri MA. Roychowdhury S, et al. Among authors: ferketich ak. J Natl Cancer Inst. 2004 Oct 6;96(19):1447-57. doi: 10.1093/jnci/djh271. J Natl Cancer Inst. 2004. PMID: 15467034
IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease.
Roychowdhury S, Blaser BW, Freud AG, Katz K, Bhatt D, Ferketich AK, Bergdall V, Kusewitt D, Baiocchi RA, Caligiuri MA. Roychowdhury S, et al. Among authors: ferketich ak. Blood. 2005 Oct 1;106(7):2433-5. doi: 10.1182/blood-2005-04-1597. Epub 2005 Jun 23. Blood. 2005. PMID: 15976176 Free PMC article.
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan KD, Emmanouilides C, Benson DM Jr, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA. Khan KD, et al. Among authors: ferketich ak. Clin Cancer Res. 2006 Dec 1;12(23):7046-53. doi: 10.1158/1078-0432.CCR-06-1571. Clin Cancer Res. 2006. PMID: 17145827 Clinical Trial.
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.
Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, Lamb TA, Grever MR, Shapiro CL, Carson WE 3rd. Bekaii-Saab TS, et al. Among authors: ferketich ak. Mol Cancer Ther. 2009 Nov;8(11):2983-91. doi: 10.1158/1535-7163.MCT-09-0820. Epub 2009 Nov 3. Mol Cancer Ther. 2009. PMID: 19887543 Free PMC article. Clinical Trial.
213 results